The beneficial cardiovascular effects seen with IL-1 blockers (anakinra and canakinumab) are in stark contrast with the lack of benefits with methotrexate, and the dose-dependent increase in heart failure-related mortality seen with the TNF-α blocker (infliximab). This evidence concerns the gene TNF and heart failure.